BUSINESS
Max Healthcare Q4FY25 net profit rises 21% on higher patient volumes; expansion plans in focus
The company announced strategic expansion initiatives to bolster its pan-India presence including plans to add 1,500 beds in FY26 through brownfield expansions at Saket, Nanavati, and Mohali hospitals.
BUSINESS
IHH’s NTK ups damages claim against Daiichi Sankyo to Rs 11,800 crore in Fortis deal dispute
The revised claim stems from NTK’s allegations that Daiichi Sankyo obstructed its 2018 open offer to acquire shares in India’s Fortis Healthcare and its subsidiary Fortis Malar Hospitals.
COMPANIES
JB Pharma eyeing 12% growth, open to acquisitions, says CEO Nikhil Chopra
Acknowledged a subdued sentiment, Chopra is confident of JB Pharma's ability to outgrow the market ‘due to its focus on progressive categories and better execution’
BUSINESS
Nobel Hygiene raise Rs 170 crore from Neo Asset Management
The investment, a mix of primary and secondary infusion, will fuel Nobel Hygiene's growth and market expansion as the adult diaper maker eyes an initial public offering
BUSINESS
Piramal Pharma’s Nandini Piramal eyes FY30 milestone amid muted FY26 outlook
The company’s FY30 goals include $2 billion in revenue, 25 percent EBITDA margin and net debt to EBITDA below 1x, says Nandini Piramal
BUSINESS
As sleeplessness rises, India turns to melatonin supplements
While a relatively recent phenomenon, its prevalence is increasing rapidly, with 85% or respondents in a survey saying they were not getting a good night’s rest
BUSINESS
JB Pharma Q4FY25 net profit Rises 15% on domestic, CDMO strength
Net profit rose to ₹146 crore, while revenue grew 10 percent to ₹949 crore.
BUSINESS
Indian drugmakers see potential tail wind in Trump’s MFN drug pricing plan
Industry executives feel that the direct-to-government sales could open new channels, giving generic manufacturers some advantage in US market known for the steep pricing pressure.
BUSINESS
Biocon’s Kiran Mazumdar-Shaw looking at biosimilar unit merger, IPO plans on hold
'The IPO market is not very predictable right now. If we are not going to get value for an IPO, then why should we do it?' Kiran Mazumdar-Shaw tells Moneycontrol
BUSINESS
Cipla eyes growth in FY26 driven by new launches, GLP-1 wave despite Revlimid headwinds
Managing Director & Global CEO Umang Vohra expressed confidence in the company's ability to expand, driven by a multi-pronged strategy across key markets.
BUSINESS
Biocon geared up to be major supplier of insulins, GLP-1 weight loss drugs: Kiran Mazumdar-Shaw
"When you look into FY26, I think we will see some very strong growth in all of our businesses," Mazumdar-Shaw said in an interview to Moneycontrol.
BUSINESS
GSK India's net profit jumps 35% in Q4FY25, led by growth of respiratory and vaccine portfolios
The board recommended a final dividend of Rs 42 per share,
BUSINESS
Trump signs order to slash US drug prices using global benchmarking, lacks clarity on generic drugs
India, which supplies nearly 40% of U.S. generics, exported $8.73 billion worth of drugs to the U.S. in 2024. Any disruption in pricing would eat into the already thin profit margins.
BUSINESS
Cautious Indian pharma awaits clarity on Trump’s prescription drug plan
Indian generic drugmakers typically operate on thin EBITDA margins of 5-15 percent on average for their base business in US, and even a small reduction in price could lead to financial unviability.
BUSINESS
India mobilizes emergency health systems amid Operation Sindoor
Union Health Minister J.P. Nadda chaired a high-level review meeting to assess the country’s emergency health systems preparedness, signaling a full-spectrum mobilization of medical infrastructure in anticipation of potential conflict-related casualties.
BUSINESS
Drugmakers, hospitals prepared for medical emergencies along border states
Sources with the influential Indian pharmaceutical body told Moneycontrol that the industry is always geared up to support the government with necessary medicines, and medical consumables.
BUSINESS
Biocon Q4 net profit surges 153%, biosimilars, generics drive growth
The company said its Board approved a fundraise of up to Rs 4,500 crore and is also evaluating a potential merger of Biocon Biologics with the parent company.
BUSINESS
Agilent opens India Solution Center to bolster scientific innovation & localized R&D
The center will serve as a hub for collaborative R&D, training, and proof-of-concept demonstrations, with dedicated zones for chromatography, mass spectrometry, spectroscopy, genomics, and cell analysis.
BUSINESS
USFDA expands unannounced inspections abroad, raising stakes for Indian drugmakers
The USFDA conducts around 3,000 foreign inspections annually, many of which involve Indian pharmaceutical plants that supply a substantial share of generic drugs to the U.S. market.
BUSINESS
Alembic Pharma eyes FY26 growth with optimism across domestic, US, and global markets
'As we ramp up our revenues and my facilities get optimally utilised, my EBITDA margin should only go up from here,' RK Baheti, CFO of the Vadodara-based company, said
BUSINESS
Aster DM Healthcare to set up another hospital in Bengaluru, invest Rs 480 crore
The hospital in Sarjapur, to be developed in phases, positions Aster among the top three healthcare providers in the region, with a total bed capacity exceeding 2,000
BUSINESS
Glenmark's novel cancer drug gets fast track status from USFDA
The Fast Track status is intended to accelerate the development and review process for drugs addressing serious conditions with unmet medical needs, potentially bringing treatments to patients faster.
BUSINESS
Suven to Divi’s: Indian CDMOs seize opportunity in pivot away from China amid global trade tensions
Concerns around the proposed US Biosecure Act, lingering trade tensions, and the spectre of potential US tariffs are compelling global pharma executives to actively court alternatives, an industry executive told Moneycontrol.
BUSINESS
Covaxin maker Bharat Biotech pivots into cell and gene therapy, eyes cost-effective innovations
The company wants to use its vaccine-making skills in developing CAR-T and gene therapies at a fraction of the cost, aspiring to be a critical part of the cell and gene therapy value chain, said its Chief Development Officer Raches Ella.
